- Trial Phase
- Phase 3 (discontinued)
- Time to Market
- Discontinued — no path to market
- Why 1/10
- Batoclimab has been discontinued following a Phase 3 TED failure — there is no scheduled binary catalyst for this drug. The company's value now rests entirely on IMVT-1402, not batoclimab. ImpactScore is 1 because batoclimab itself drives no future share-price move.
Batoclimab is a discontinued asset — investors should focus entirely on Immunovant's next-generation FcRn inhibitor IMVT-1402, which has key data readouts in H2 2026 (D2T RA and CLE) and 2027 (Graves' disease, myasthenia gravis). The batoclimab Phase 3 TED failure triggered a pipeline pivot, and IMVT-1402's success or failure will determine the stock's trajectory.
Price Chart
Executive Summary
Batoclimab (IMVT-1401) is an anti-FcRn monoclonal antibody developed by Immunovant, Inc. (Nasdaq: IMVT) for autoimmune diseases. Its lead program — a Phase 3 trial in Thyroid Eye Disease (TED) — failed to meet its primary endpoint, leading Immunovant to discontinue the drug entirely in early 2026 and incur $39M in wind-down costs. All batoclimab trials (Phase 2 CIDP, Phase 2 Graves' disease, Phase 3 TED extension) have been terminated or completed with no regulatory path forward. The company has pivoted to a next-generation FcRn inhibitor, IMVT-1402, which is now the sole value driver. Batoclimab itself is a dead asset with no future catalysts.
How It Works
Batoclimab is an antibody that blocks the FcRn receptor, which normally recycles IgG antibodies in the bloodstream and prevents them from being broken down. By blocking FcRn, batoclimab lowers the level of all IgG antibodies circulating in the body. This is useful in autoimmune diseases where the immune system produces harmful IgG antibodies that attack the body's own tissues — reducing those antibodies can reduce disease activity.
Trial Status
Batoclimab's Phase 3 trial in Thyroid Eye Disease (NCT05524571, 86 patients) completed in March 2026 but failed to meet its primary endpoint. A Phase 2 proof-of-concept trial in Graves' disease (NCT05907668, 32 patients) completed with results. Two Phase 2 CIDP trials (NCT05581199, 94 patients; NCT07188844, 26 patients) were terminated in July 2026. A Phase 3 TED extension study (NCT05517447, 109 patients) was terminated in April 2026. All programs have been discontinued.
The Two-Sided Case
Upcoming Catalysts
- None — batoclimab has been discontinued. All future catalysts for Immunovant relate to IMVT-1402, not batoclimab.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Immunovant, Inc. 8-K IMVT ·Originating report